Universidad de Granada Digibug
 

Repositorio Institucional de la Universidad de Granada >
2.-Revistas >
ARS Pharmaceutica >
Ars Pharma 2009, Vol. 50 >
APh, vol. 50(3) >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10481/27459

Title: Pharmaceutical co-crystals - a review
Authors: Sekhon, Bhupinder Singh
Issue Date: 2009
Abstract: Co-crystallization alters the molecular interactions and composition of pharmaceutical materials, and is considered better alternatives to optimize drug properties. Co-crystals consists of API and a stoichiometric amount of a pharmaceutically acceptable co-crystal former. Pharmaceutical co-crystals are nonionic supramolecular complexes and can be used to address physical property issues such as solubility, stability and bioavailability in pharmaceutical development without changing the chemical composition of the API. Co-crystals can be constructed through several types of interaction, including hydrogen bonding, pi-stacking, and van der Waals forces. Co-crystals High Throughput provides information on relationship between formation and chemical structure of the API and conformer. Factors affecting co-crystal stability are reported and a co-crystal is only expected to form if it is thermodynamically more stable than the crystals of its components. Phase transformations induced during processing/storage affects the mechanisms of conversion of crystalline drugs to co-crystals. Pharmaceutical co-crystals could play a major part in the future of API formulation and can be employed for chiral resolution.
Publisher: Universidad de Granada, Facultad de Farmacia
Keywords: Co-crystallization
Heterosynthon
Hydrogen bonding
Pharmaceutical co-crystal
Polymorph
URI: http://hdl.handle.net/10481/27459
ISSN: 0004-2927
Rights : Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Citation: Sekhon, B.S. Pharmaceutical co-crystals- a review. Ars Pharm, 2009; 50(3): 99-117. [http://hdl.handle.net/10481/27459]
Appears in Collections:APh, vol. 50(3)

Files in This Item:

File Description SizeFormat
ars Pharm 2009;50(3)99-117.pdf220.09 kBAdobe PDFView/Open
Recommend this item

This item is licensed under a Creative Commons License
Creative Commons

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! OpenAire compliant DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback

© Universidad de Granada